Page 2 - Charles Large News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulat

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulat
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of pennsylvaniaEthan goldbergHospital of the university pennsylvaniaIp groupAutifony therapeutics limitedSv health investorsAutifony therapeuticsAutifony therapeutics ltdOffice of orphan products developmentInternational biotechnology trustMyoclonus epilepsyChannel mutationFederal foodOrphan products developmentCharles large

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of pennsylvaniaGiulia lasagni batoul aliEthan goldbergSv health investorsAutifony therapeutics limitedAutifony therapeuticsAutifony therapeutics ltdOffice of orphan products developmentHospital of the university pennsylvaniaIp groupInternational biotechnology trustTherapeutics limitedMyoclonus epilepsyChannel mutationFederal food

Teitur Trophics Raises EUR 28M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Mathias ollendorffSimon molgaardCasper breumAnders dalbyFredrik lehmannSimon glerupMilla koistinahoTeitur trophicsInnovestor life science fundSunstone life science venturesSound bioventuresLife science fundCharles largeSusanne stuffersTeitur boardFrontotemporal dementia

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor's Life Science Fund and P53 InvestDiscovery of a novel mechanism with

United statesDennis riedlMathias ollendorffSimon molgaardCasper breumSimon glerupAnders dalbyFredrik lehmannMilla koistinahoPrnewswire teitur trophicsTeitur trophicsBioinnovation instituteIndustrifonden is sweden venture capital fundInnovestor life science fundAarhus universitySunstone life science ventures

Brain Gamma Oscillations: A Novel Target in Schizophrenia?

Targeting a potassium channel linked to brain gamma oscillations may offer a novel means of treating schizophrenia after patients showed improved symptom scores.

United statesUnited kingdomJamesm mcnallySchizophrenia international research societyHarvard medical schoolCharles largeAutifony therapeuticsMedscape medical newsNegative syndrome scaleNeuroleptic drugsDrug developmentClinical researchClinical trialsLinical studiesHealthcare and medical technologyEalth and medical tech